C1511790||Detection
C0027625||circulating tumour cells
C0476089||endometrial cancer
C0376636||management
C0220825||evaluate
C0027625||circulating tumour cells
C0027625||circulating tumour cells
C0476089||endometrial cancer
C0476089||endometrial cancer
C2603343||study
C0332167||high-risk
C0476089||endometrial cancer
C0332167||high-risk
C1300661||grade 3, non-endometrioid, myometrial invasion â‰¥1/2
C1300072||stage III-IV
C3640764||high-intermediate-risk
C1300661||(grade 2-3, endometrioid, myometrial invasion <1/2
C1300072||stage I-II
C0027625||circulating tumour cells
C1511790||detected
C0430022||CellSearch system
C0027625||CTC
C0730483||serum tumour marker CA125 / HE4 status
C0430022||Chi-squared test
C1708064||Fisher's exact test
C1868979||pharmacodynamic effect
C1511790||detected
C0677850||adjuvant therapy
C0027625||circulating tumour cells
C0027625||circulating tumour cells
C0205064||cervical
C0027625||CTC
C1446409||positive
C1511790||detected
C0332167||high-risk
C3640764||high-intermediate-risk groups
C0027625||circulating tumour cells
C0229671||serum
C0006610||CA125
C2707001||HE4
C1446409||positive
C0229671||serum
C0041366||conventional tumour markers
C0027625||circulating tumour cells
C1511790||detected
C3665472||chemotherapy
C2603343||study
C0243095||distant metastases or recurrence
C0027625||CTC
C1446409||positive
C1522577||follow-up
C0027625||CTC s
C0205064||cervical
C0476089||endometrial cancer
C0027625||circulating tumour cells
C0677850||adjuvant therapies
C0220825||Assessment
C0027625||circulating tumour cells
C0376636||management
C0332167||high-risk
C0476089||endometrial cancer